title: The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy.
abstract: This study aimed at evaluating the usefulness of topoisomerase II alpha (TOP2A) for predicting the effect of anthracycline-based neoadjuvant chemotherapy in breast cancer. The TOP2A status was examined using fluorescent in situ hybridization (FISH) in 14 pre-chemotherapeutic breast cancer tissues, and was also assessed by immunohistochemistry (IHC) in 14 pairs of pre- and post-chemotherapeutic breast cancer specimens. TOP2A gene aberration by IHC tended to show a correlation with pathological responses but this was not statistically significant (p=0.060). On the other hand, the low TOP2A/CEP17 ratio correlated with good pathological responses (p=0.012). TOP2A overexpression was not significantly associated with response (p=0.580). Our results thus suggest that the TOP2A/CEP17 ratio may be a useful predictor of the effects of anthracycline-based neoadjuvant chemotherapy in breast cancer.
authors.affiliation: Division of Anatomic and Surgical Pathology, Yokohama City University Medical Center, Minami-ku, Yokohama, Japan. kw1151@urahp.yokohama-cu.ac.jp
authors.forename: Kae
authors.initials: K
authors.lastname: Kawachi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sasaki
authors.forename: Ayumi
authors.initials: A
authors.lastname: Murakami
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Ayako
authors.initials: A
authors.lastname: Kito
authors.forename: Ikuko
authors.initials: I
authors.lastname: Ota
authors.forename: Daisuke
authors.initials: D
authors.lastname: Shimizu
authors.forename: Akinori
authors.initials: A
authors.lastname: Nozawa
authors.forename: Yoji
authors.initials: Y
authors.lastname: Nagashima
authors.forename: Rikuo
authors.initials: R
authors.lastname: Machinami
authors.forename: Ichiro
authors.initials: I
authors.lastname: Aoki
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics*; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D000075223:Poly-ADP-Ribose Binding Proteins
chemical_list: D018943:Anthracyclines; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D004250:DNA Topoisomerases, Type II; C000618811:TOP2A protein, human